Healthcare Industry News: ultrasound imaging
News Release - July 14, 2006
Boston Scientific's iLab(TM) Ultrasound Imaging System Makes it Easier to View Within the Heart and VesselsNew system enhances diagnosis and treatment of blocked vessels and heart disorders
NATICK, Mass., July 14 (HSMN NewsFeed) -- Boston Scientific Corporation (NYSE: BSX ) today announced the U.S. launch of its iLab(TM) ultrasound imaging System. Intravascular ultrasound (IVUS) allows physicians to see images inside the heart and inside coronary and peripheral arteries to assist with diagnosis. The Company, the worldwide market leader in IVUS technology, will make the system available immediately.
This first system of its kind, the iLab(TM) ultrasound imaging System can be directly installed into the cardiac catheterization lab or radiology suite, enabling physicians to quickly and easily incorporate IVUS technology into their procedures every day. The system's tableside controller gives physicians control of the device within the sterile field, and the unique Dynamic Review(TM) feature enhances image interpretation. The system's touch panel provides an intuitive user interface with prompts that correspond to the particular stage of the procedure. In addition, the easy-to-upgrade platform allows for future innovation to keep pace with a fast-moving health care environment.
"With the introduction of more sophisticated medical devices such as drug-eluting stents, physicians are treating more complex cases than ever before," said Paul Teirstein, M.D., of Scripps Green Hospital in LaJolla, CA. "That makes the iLab ultrasound imaging System an even more important part of my practice. Now I can obtain the images I need quickly and easily. This lets me routinely quantitate the patient's disease, and make an informed diagnosis."
With IVUS, a tiny catheter is inserted into the heart or into a coronary or peripheral vessel where high-frequency sound waves reflect off tissue or vessel walls. The reflected sound waves create a cross-sectional image from within the vessel or heart to aid in visualizing vessel and heart structure. IVUS technology also provides physicians with a better understanding of blocked vessels, which allows for proper selection and placement of stents and other devices to restore blood flow at the site of the blockage.
"Boston Scientific is making it easier for physicians to use IVUS technology every day," said Hank Kucheman, President of Boston Scientific's Interventional Cardiology business. "Historically, a barrier to regular IVUS usage has been the need for more user-friendliness. By installing the system right into the lab and putting controls into their hands, physicians now have immediate access to this important technology."
In addition to the introduction of this new IVUS system, Boston Scientific also offers extensive training and education with its iLearn(TM) Education Series. Designed for physicians, fellows, nurses and technologists, the iLearn series consists of classroom and hands-on courses that build knowledge and confidence to incorporate IVUS into daily practice. The combination of technology that is easy to use and a care delivery team with enhanced skills will help IVUS become a routine diagnostic choice for enhanced patient care.
Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: http://www.bostonscientific.com.
This press release contains forward-looking statements. Boston Scientific wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, risks associated with new product development and commercialization, clinical trials, intellectual property, regulatory approvals, competitive offerings, Boston Scientific's overall business strategy, and other factors described in Boston Scientific's filings with the Securities and Exchange Commission.
Source: Boston Scientific
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsBoston Scientific Receives FDA Approval for Expanded Labeling of WATCHMAN FLX(TM) LAAC Device for Dual Anti-Platelet Therapy as Post-Procedural Medication Option
Boston Scientific Announces Acquisition of Obsidio, Inc.
Boston Scientific Announces Agreement to Purchase Majority Stake of M.I.Tech Co., Ltd from Synergy Innovation Co., Ltd